Pharmacology of argatroban

References

• Kobayashi W, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin. Thromb. Hemost.23, 531–534 (1997).
   PubMed Web of Science ®Google Scholar
• Ota K, Akizawa T, Hirasawa Y, Agishi T, Matsui N. Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol. Dial. Transplant.18, 1623–1630 (2003).
   PubMed Web of Science ®Google Scholar
• Miyata S, Yamamoto H, Kamei M et al. Heparin-induced thrombocytopenia clinical studies and the efficacy of argatroban in Japan. Semin. Thromb. Hemost.34(Suppl. 1), 37–47 (2008).
   Web of Science ®Google Scholar
• Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists. Chest133, S160–S198 (2008).
   PubMed Web of Science ®Google Scholar
• Duggan ST, Scott LJ, Plosker GL. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Drugs69(13), 1829–1851 (2009).
   PubMed Web of Science ®Google Scholar
• Carreiro J, Ansell J. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opin. Investig. Drugs17(12), 1937–1945 (2008).
   PubMed Web of Science ®Google Scholar
• Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy28(11), 1354–1373 (2008).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin. Pharmacokinet.48(1), 1–22 (2009).
   PubMed Web of Science ®Google Scholar
• Bush LR. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc. Drug Rev.9(3), 247–263 (1991).
   Google Scholar
• Kikumoto R, Tamao Y, Tezuka T et al. Selective inhibition of thrombin by (2R, 4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid. Biochemistry23, 85–90 (1984).
   PubMed Web of Science ®Google Scholar
• Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of th e synthetic thrombin inhibitor argatroban on fibrin-or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb. Haemost.72, 381–386 (1994).
   PubMed Web of Science ®Google Scholar
• Hara H, Yoshikuni T, Kikumoto R. Effect of argatroban (MD-805) on platelet function. Jap. J. Pharm. Ther.14(Suppl. 1), 13–19 (1986).
   Google Scholar
• Ueki Y, Matsumoto K, Kizaki Y et al. Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease: placebo-controlled study. J. Thromb. Thrombolysis8(2), 131–137 (1999).
   PubMed Web of Science ®Google Scholar
• Rawson TE, Van Gorp KA, Yang J, Kogan TP. Separation of 21-(R)- and 21-(S)- argatroban: solubility and activity of the individual diastereoisomers. J. Pharm. Sci.82(6), 672–673 (1993).
   PubMed Web of Science ®Google Scholar
• Yeh R, Jang IK. Argatroban; update. Am. Heart J.151, 1131–1138 (2006).
   PubMed Web of Science ®Google Scholar
• Ansara AJ, Arif S, Warhurst RD. Weight-based argatroban dosing nomogram for treatment of heparin-induced-thrombocytopenia. Ann. Pharmacother.43(1), 9–18 (2009).
   PubMed Web of Science ®Google Scholar
• Ahsan A, Ahmad S, Iqbal O et al. Comparative studies on the biochemical and pharmacological properties of a major metabolite of argatroban (M1) [Abstract]. Thromb. Haemost.178(Suppl. 1), 92 (1997).
   Google Scholar
• Hursting MJ, Alford KL, Becker JC et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin. Thromb. Hemost.23, 503–516 (1997).
   PubMed Web of Science ®Google Scholar
• Hursting MJ, Murray PT. Argatroban anticoagulation in renal dysfunction: a literature analysis. Nephron109(2), 80–94 (2008).
   Google Scholar
• Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy20, 318–329 (2000).
   PubMed Web of Science ®Google Scholar
• Guzzi LM, McCollum DA, Hursting MJ. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J. Thromb. Thrombolysis22(3), 169–176 (2006).
   PubMed Web of Science ®Google Scholar
• Husting MJ, Jang IK. Impact of renal function on argatroban therapy during percutaneous coronary intervention. J. Thromb. Thrombolysis29, 1–7 (2010).
   PubMed Web of Science ®Google Scholar
• Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest129(5), 1167–1175 (2006).
   PubMed Web of Science ®Google Scholar
• Hursting MJ, Dubb J, Verme-Gibboney CN. Argatroban anticoagulation in pediatric patients: a literature analysis. J. Pediatr. Hematol. Oncol.28(1), 4–10 (2006).
   PubMed Web of Science ®Google Scholar
• Hursting MJ, Jang IK. Effect of body mass index on argatroban therapy during percutaneous coronary intervention. J. Thromb. Thrombolysis25(3), 273–279 (2008).
   PubMed Web of Science ®Google Scholar
• Begelman SM, Baghdasarian SB, Singh IM, Militello MA, Hursting MJ, Bartholomew JR. Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure. J. Intensive Care Med.23(5), 313–320 (2008).
   PubMedGoogle Scholar
• Keegan SP, Gallagher EM, Ernst NE, Young EJ, Mueller EW. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia. Ann. Pharmacother.43, 19–27 (2009).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. Chest133, S340–S380 (2008).
   PubMedGoogle Scholar
• Clark RJ, Mayo G, Fitzgerald GA, Fitzgerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation83, 1510–1518 (1991).
   PubMed Web of Science ®Google Scholar
• Tran JQ, DiCicco RA, Sheth SB. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J. Clin. Pharmacol.39, 513–519 (1999).
   PubMed Web of Science ®Google Scholar
• Inglis AL, Sheth SB, Hursting MJ, Tenero DM, Graham AM, DiCicco RA. Investigation of interaction between argatroban and acetaminophen, lidocaine, or digoxin. Am. J. Health Syst. Pharm.59, 1258–1266 (2002).
   PubMed Web of Science ®Google Scholar
• Tamao Y, Yamamoto T, Hirata T, Kinusaga M, Kikumoto R. Effect of argatroban on blood coagulation. Jap. J. Pharm. Ther.14(5), 7–12 (1986).
   Google Scholar
• Walenga JM, Ahmad S, Hoppensteadt D, Iqbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb. Res.105, 401–405 (2002).
   PubMed Web of Science ®Google Scholar
• Jeske W, Walenga JM, Lewis BE, Fareed J. Pharmacology of argatroban. Expert Opin. Investig. Drugs8, 625–654 (1999).
   PubMedGoogle Scholar
• Fareed J, Jeske WP. Small-molecule direct antithrombins: argatroban. Best Pract. Res. Clin. Haematol.17(1), 127–138 (2004).
   PubMed Web of Science ®Google Scholar
• Fareed J, Hoppensteadt D, Iqbal O, Tobu M, Lewis BE. Practical issues in the development of argatroban: a perspective. Pathophys. Haemost. Thromb.32(Suppl. 3), 56–65 (2002).
   PubMedGoogle Scholar
• Weitz JI, Crowther MA. New anticoagulants; current status and future potential. Am. J. Cardiovasc. Drugs3, 201–209 (2003).
   PubMedGoogle Scholar
• Lewis BE, Walenga JM, Hursting MJ. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Cardiovasc. Rev. Rep.23(8), 445–454 (2002).
   Google Scholar
• LaMonte MP, Brown PM, Hursting MJ. Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor. Future Drugs3(1), 31–41 (2005).
   Google Scholar
• Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood101(1), 31–37 (2003).
   PubMed Web of Science ®Google Scholar
• Levine RL, Hursting MJ, Drexler A, Lewis BE, Francis JL. Heparin-induced thrombocytopenia in the emergency department. Ann. Emerg. Med.44(5), 511–515 (2004).
   PubMed Web of Science ®Google Scholar
• Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia. A critical review. Arch. Intern. Med.164, 361–369 (2004).
   PubMedGoogle Scholar
• Hursting MJ, Soffer J. Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia. Drug Saf.32(3), 203–218 (2009).
   PubMed Web of Science ®Google Scholar
• Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation103, 1838–1843 (2001).
   PubMed Web of Science ®Google Scholar
• Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG; Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch. Intern. Med.163, 1849–1856 (2003).
   PubMed Web of Science ®Google Scholar
• Matthai WH, Hursting MJ, Lewis BE, Kelton JG. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb. Res.116(2), 121–126 (2005).
   PubMed Web of Science ®Google Scholar
• Greinacher A, Janssens U, Berg G et al.; for the Heparin-Associated Thrombocytopenia Study (HAT) Investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation100(6), 587–593 (1999).
   PubMed Web of Science ®Google Scholar
• Greinacher A, Volpel H, Janssens U et al.; for the HIT Investigators Group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation99, 73–80 (1999).
   PubMed Web of Science ®Google Scholar
• Veach SA, Franks AM, Allan MC. Severe anaphylactic reaction after repeated intermittent exposure to lepirudin. Pharmacotherapy27(5), 760–765 (2007).
   PubMed Web of Science ®Google Scholar
• Harenberg J, Jorg I, Fenyvesi T, Piazolo L. Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban. J. Thromb. Thrombolysis19(1), 65–69 (2005).
   PubMed Web of Science ®Google Scholar
• Kemkes-Matthes B, Walenga JM, Harenberg J, Fareed J. Argatroban treatment for patients with intolerance to heparin and hirudin. Clin. Appl. Thromb. Hemost.11(1), 99–103 (2005).
   PubMed Web of Science ®Google Scholar
• Smythe MA, Stephens JL, Koerber JM, Mattson JC. A comparison of lepirudin and argatroban outcomes. Clin. Appl. Thromb. Hemost.11(4), 371–374 (2005).
   PubMed Web of Science ®Google Scholar
• Bartholomew JR, Pietrangeli CE, Hursting MJ. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging24(6), 489–499 (2007).
   PubMed Web of Science ®Google Scholar
• Lewis BE, Matthai WH Jr, Cohen M et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin induced thrombocytopenia. Catheter Cardiovasc. Interv.57, 177–184 (2002).
   PubMed Web of Science ®Google Scholar
• Cruz-Gonzalez I, Sanchez-Ledesma M, Osakabe M et al. What is the optimal anticoagulation level with argatroban during percutaneous coronary intervention? Blood Coagul. Fibrinolysis19(5), 401–404 (2008).
   PubMed Web of Science ®Google Scholar
• Jang IK, Lewis BE, Matthai WH, Kleiman NS. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, non-randomized trial. J. Thromb. Thrombolysis18(1), 31–37 (2004).
   PubMed Web of Science ®Google Scholar
• Cox DS, Kleiman NS, Boyle DA et al. Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIb/IIIa receptor antagonist in patients undergoing percutaneous coronary intervention. J. Clin. Pharm.44(9), 981–990 (2004).
   PubMed Web of Science ®Google Scholar
• Cruz-Gonzalez I, Sanchez-Ledesma M, Baron SJ et al. Efficacy and safety or argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome. J. Thromb. Thrombolysis25(2), 214–218 (2008).
   PubMed Web of Science ®Google Scholar
• Hirahara T, Kubo N, Ohmura N et al. Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction. J. Cardiol.44(2), 47–52 (2004).
   PubMedGoogle Scholar
• Itoh T, Nonogi H, Miyazaki S et al. Local delivery of argatroban for the prevention of restenosis after coronary balloon angioplasty: a prospective randomized pilot study. Circ. J.68(7), 615–622 (2004).
   PubMed Web of Science ®Google Scholar
• Roessig L, Genth-Zotz S, Rau M et al. Argatroban for elective percutaneous coronary intervention: the ARG-EO4 multi-center study. Int. J. Cardiol. DOI: 10.1016/j.ijcard.2010.02.044. (2010) (Epub ahead of print).
   Google Scholar
• Cetta F, Graham LC, Wrona LL, Arruda MJ, Walenga JM. Argatroban use during pediatric interventional cardiac catheterization. Cath. Cardiovasc. Interv.61(1), 147–149 (2004).
   PubMed Web of Science ®Google Scholar
• Vermeer F, Vahanian A, Fels PW et al. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI study. J. Thromb. Thrombolysis10, 233–240 (2000).
   PubMed Web of Science ®Google Scholar
• Nagatsuna T, Nomura S, Suehiro E, Fujisawa H, Koizumi H, Suzuki M. Systemic administration of argatroban reduces secondary brain damage in a rat model of intracerebral hemorrhage; histopathological assessment. Cerebrovasc. Dis.19(3), 192–200 (2005).
   PubMed Web of Science ®Google Scholar
• LaMonte MP, Nash ML, Wang DZ et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke35(7), 1677–1682 (2004).
   PubMed Web of Science ®Google Scholar
• LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit. Care Med.32(4), 976–980 (2004).
   PubMed Web of Science ®Google Scholar
• Murray PT, Reddy BV, Grossman EJ et al. A prospective comparison of three argatroban regimens during hemodialysis in end-stage renal disease. Kidney Int.66(6), 2446–2453 (2004).
   PubMed Web of Science ®Google Scholar
• Tang IY, Cox DS, Patel K et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann. Pharmacother.39(2), 231–236 (2005).
   PubMed Web of Science ®Google Scholar
• Young G, Yonekawa KE, Nakagawa P, Nugent DJ. Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion19(5), 283–288 (2004).
   PubMed Web of Science ®Google Scholar
• Johnston N, Wait M, Huber L. Argatroban in adult extracorporeal membrane oxygenation. J. Extra Corpor. Technol.34, 281–284 (2002).
   PubMedGoogle Scholar
• Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol. Oncol. Clin. N. Am.14, 4445–4457 (2000).
   Google Scholar
• Mejak B, Giacomuzzi C, Heller E et al. Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia. J. Extra Corpor. Technol.36(2), 178–181 (2004).
   PubMedGoogle Scholar
• Kawada T, Mieda T, Abe H et al. Left heart bypass with the bio-medicus centrifugal pump by the use of an antithrombin agent, argatroban. Kyobu Geka47, 803–808 (1994).
   PubMedGoogle Scholar
• Edwards JT, Hamby JK, Worrall NK. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann.Thorac. Surg.75, 1622–1624 (2003).
   PubMed Web of Science ®Google Scholar
• Kamei M, Miyata S, Niwaya K et al. Successful argatroban anticoagulant management for left ventricular assist system implantation in two patients with heparin-induced thrombocytopenia type II. J. Thromb. Hemost.1(Suppl. 1), P1162 (2003).
   Google Scholar
• Tokuda Y, Matsumoto M, Sugita T et al. Vascular surgery using argatroban in a patient with a history of heparin-induced thrombocytopenia. Circ. J.67, 899–890 (2003).
   Google Scholar
• Malherbe S, Tsui BCH, Stobart K, Koller J. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology100, 443–445 (2004).
   PubMed Web of Science ®Google Scholar
• Dyke PC, Russo P, Mureebe L, Russo J, Tobias JD. Argatroban for anticoagulation during cardiopulmonary bypass in an infant. Paediatr. Anaesth.15, 328–333 (2005).
   PubMed Web of Science ®Google Scholar
• Mejak B, Giacomuzzi C, Shen I, Boshkov L, Ungerleider R. Cardiopulmonary bypass using argatroban as an anticoagulant for a 6.0‑kg pediatric patient. J. Extra. Corpor. Technol.37, 303–305 (2005).
   PubMedGoogle Scholar
• Alsoufi B, Boshkov LK, Kirby A et al. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Ann.7, 155–171 (2004).
   PubMedGoogle Scholar
• Kieta DR, McCammon AT, Holman WL, Nielsen VG. Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation. Anesth. Analg.96, 956–958 (2003).
   PubMed Web of Science ®Google Scholar
• Ohno H, Higashidate M, Yokosuka T. Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary artery bypass. Heart Vessels18, 40–42 (2003).
   PubMed Web of Science ®Google Scholar
• Arnoletti JP, Whitman GJR. Heparin-induced thrombocytopenia in coronary bypass surgery. Ann. Thorac. Surg.68, 576–578 (1999).
   PubMed Web of Science ®Google Scholar
• Ide H, Fujiki T, Sato M, Endo H, Imamura K, Sudo K. Off-pump coronary artery bypass for a heparin-allergic patient. Jpn. J. Thorac. Cardiovasc. Surg.49, 250–254 (2001).
   PubMedGoogle Scholar
• Cannon MA, Butterworth J, Riley RD, Hyland JM. Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery. Ann. Thorac. Surg.77, 711–713 (2004).
   PubMed Web of Science ®Google Scholar
• Lubenow N, Selleng S, Wollert HG, Eichler P, Mullejans B, Greinacher A. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann. Thorac. Surg.75(2), 577–579 (2003).
   PubMed Web of Science ®Google Scholar
• Hoffman WD, Czyz Y, McCollum DA, Hursting MJ. Reduced argatroban doses after coronary artery bypass graft surgery. Ann. Pharmacother.42(3), 309–316 (2008).
   PubMed Web of Science ®Google Scholar
• Hursting MJ, Verme-Gibboney CN. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study. J. Cardiovasc. Pharm.52(6), 561–566 (2008).
   PubMed Web of Science ®Google Scholar
• Gray E, Harenberg J; on behalf of the ISTH Control of Anticoagulation SSC Working Group on Thrombin Inhibitors. Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban. J. Thromb. Haemost.3, 2096–2097 (2005).
   PubMed Web of Science ®Google Scholar
• Francis JL, Hursting MJ. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents. Blood Coagul. Fibrinolysis16, 251–257 (2005).
   PubMed Web of Science ®Google Scholar
• Iqbal O, Ahmad S, Lewis BE, Walenga JM, Rangel Y, Fareed J. Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology. Clin. Appl. Thromb. Hemost.8(3), 217–224 (2002).
   PubMed Web of Science ®Google Scholar
• Gosselin RC, Dager WE, King JH et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin and argatroban, on prothrombin time and INR values. Am. J. Clin. Pathol.121, 593–599 (2004).
   PubMed Web of Science ®Google Scholar
• Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb. Haemost.85, 435–440 (2001).
   PubMed Web of Science ®Google Scholar
• Harder S, Graff J, Klinkhardt U et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on PT, aPTT and ecarin clotting time. Thromb. Haemost.91, 1137–1145 (2004).
   PubMed Web of Science ®Google Scholar
• Walenga JM, Drenth AF, Mayuga M et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. Clin. Appl. Thromb. Hemost.14(3), 325–331 (2008).
   PubMed Web of Science ®Google Scholar
• Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin. Appl. Thromb. Hemost.11(3), 279–287 (2005).
   PubMed Web of Science ®Google Scholar
• Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants. Chest133, S141–S159 (2008).
   PubMedGoogle Scholar
• Gosselin RC, Dager WE, King JH et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am. J. Clin. Pathol.121, 593–599 (2004).
   PubMed Web of Science ®Google Scholar
• Gorman R, Gordan L, Zumberg M, Kitchens C. Successful use of argatroban as an anticoagulant in burn-related severe acquired antithrombin III deficiency after heparin failure. Thromb. Haemost.86, 1596–1597 (2001).
   PubMed Web of Science ®Google Scholar